Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFIRINOX with chemo‑radiotherapy for borderline resectable or locally advanced pancreatic cancer
2011-000703-40Phase 2Completed
- Sponsor
- University Hospital Odense
- Start
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of FOLFIRINOX in pancreatic adenocarcinoma (PDAC), sponsored by University Hospital Odense. Primary endpoint: Primary efficacy. Started Jun 2011; status: completed.
02
Drugs
FOLFIRINOX
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2011-000703-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000703-40.